Introduction_NN #_NN
This_DT review_NN addresses_VBZ established_VBN and_CC emerging_VBG glycan_NN biomarkers_NNS for_IN detection_NN ,_, prognosis_NN and_CC novel_JJ therapeutic_JJ strategies_NNS against_IN gastric_JJ and_CC colorectal_JJ carcinomas_NNS ._.
These_DT are_VBP among_IN the_DT most_RBS prevalent_JJ and_CC deadliest_JJS gastrointestinal_JJ tract_NN malignancies_NNS in_IN western_JJ populations_NNS 1_CD ,_, mostly_RB due_IN to_IN late_JJ diagnosis_NN ,_, rapid_JJ metastatic_JJ spread_NN and_CC scarce_JJ efficient_JJ therapeutics_NNS 2_CD -_SYM 4_CD ._.
In_IN fact_NN ,_, current_JJ treatments_NNS rely_VBP essentially_RB on_IN surgery_NN associated_VBN with_IN (_-LRB- neo_NN )_-RRB- adjuvant_NN chemotherapy_NN ,_, which_WDT is_VBZ highly_RB toxic_JJ and_CC provides_VBZ only_RB modest_JJ results_NNS for_IN advanced_JJ stage_NN patients_NNS 2,5_CD -_SYM 7_CD ._.
Over_IN the_DT past_JJ ten_CD years_NNS the_DT introduction_NN of_IN targeted_VBN therapeutics_NNS and_CC immunotherapy_NN has_VBZ allowed_VBN significant_JJ ,_, but_CC yet_CC insufficient_JJ ,_, improvements_NNS in_IN disease_NN management_NN 8_CD -_SYM 10_CD ._.
As_IN the_DT oncology_JJ field_NN moves_VBZ toward_IN precision_NN medicine_NN and_CC patient_JJ -_HYPH tailored_VBN therapeutic_JJ solutions_NNS ,_, it_PRP becomes_VBZ imperative_JJ to_TO accomplish_VB a_DT more_RBR integrative_JJ and_CC in_IN -_HYPH depth_NN overview_NN of_IN the_DT molecular_NN nature_NN of_IN tumors_NNS 11_CD -_SYM 13_CD ._.
#_NN Alterations_NNS in_IN protein_NN glycosylation_NN are_VBP among_IN the_DT main_JJ molecular_NN events_NNS accompanying_VBG oncogenic_JJ transformations_NNS in_IN the_DT gastric_NN and_CC colorectal_JJ tracts_NNS 14_CD -_SYM 16_CD ._.
In_IN fact_NN ,_, protein_NN glycosylation_NN is_VBZ one_CD of_IN the_DT most_RBS frequent_JJ ,_, complex_JJ and_CC plastic_JJ posttranslational_JJ modifications_NNS of_IN membrane_NN -_HYPH bound_JJ and_CC secreted_VBN proteins_NNS 17_CD ._.
Glycans_NNS play_VBP a_DT key_JJ role_NN in_IN protein_NN @_IN @_IN @_IN @_IN @_IN @_IN @_IN @_IN @_IN @_IN several_JJ cell_NN functions_NNS ,_, such_JJ as_IN cell_NN adhesion_NN ,_, migration_NN and_CC signaling_NN ,_, as_RB well_RB as_IN modulate_VB immune_JJ recognition_NN and_CC host_NN -_HYPH pathogen_NN interactions_NNS 16,18_CD -_SYM 20_CD ._.
Protein_NN glycosylation_NN results_NNS from_IN the_DT highly_RB coordinated_VBN action_NN of_IN nucleotide_JJ sugar_NN transporters_NNS and_CC sugar_NN biosynthesis_NN pathways_NNS ,_, involving_VBG glycosyltransferases_NNS (_-LRB- GTs_NNP )_-RRB- and_CC glycosidases_NNS in_IN the_DT endoplasmatic_JJ reticulum_NN and_CC the_DT Golgi_NNP apparatus_NN ._.
As_IN such_JJ ,_, several_JJ factors_NNS may_MD influence_VB glycan_NN biosynthesis_NN ,_, namely_RB ,_, the_DT under_NN or_CC overexpression_NN of_IN glycosyltransferases_NNS ,_, the_DT impairment_NN of_IN glycosyltransferase_NN chaperone_NN function_NN ,_, altered_VBN glycosidase_NN activity_NN ,_, changes_NNS in_IN the_DT tertiary_JJ conformation_NN of_IN a_DT given_VBN peptide_NN or_CC growing_VBG glycan_NN ,_, and_CC the_DT availability_NN of_IN sugar_NN nucleotide_NN donors_NNS ,_, cofactors_NNS and_CC acceptor_NN substrates_NNS 21,22_CD ._.
The_DT mislocalization_NN of_IN glycosyltranferases_NNS throughout_IN the_DT secreting_VBG organelles_NNS also_RB contributes_VBZ to_IN significant_JJ alterations_NNS in_IN cancer_NN -_HYPH associated_VBN protein_NN glycosylation_NN patterns_NNS 23_CD -_SYM 25_CD ._.
Two_CD main_JJ classes_NNS of_IN glycans_NNS can_MD be_VB found_VBN at_IN cell_NN -_HYPH surface_NN glycoproteins_NNS :_: i_LS )_-RRB- O_NN -_HYPH glycans_NNS ,_, being_VBG the_DT most_RBS common_JJ O_NN -_HYPH glycan_NN that_WDT is_VBZ initiated_VBN in_IN the_DT Golgi_NNP by_IN the_DT attachment_NN of_IN a_DT GalNAc_NNP residue_NN to_IN the_DT hydroxyl_NN groups_NNS of_IN serine_NN (_-LRB- Ser_NN )_-RRB- or_CC threonine_NN (_-LRB- Thr_NN )_-RRB- amino_NN acids_NNS of_IN a_DT given_VBN polypeptide_NN chain_NN (_-LRB- @_IN @_IN @_IN @_IN @_IN @_IN @_IN @_IN @_IN @_IN O_NNP -_HYPH glycosylation_NNP )_-RRB- 26_CD ;_: and_CC ii_CD )_-RRB-
N_FW -_HYPH glycans_NNS ,_, whose_WP$ biosynthesis_NN initiates_VBZ in_IN the_DT endoplasmatic_JJ reticulum_NN by_IN the_DT addition_NN of_IN an_DT oligosaccharide_JJ chain_NN to_IN an_DT asparagine_NN (_-LRB- Asn_NNP )_-RRB- residue_NN within_IN consensus_NN peptide_NN sequences_NNS of_IN Asn_NNP -_HYPH X_NNP -_HYPH Ser_NNP /_SYM Thr_NNP (_-LRB- X_NN denotes_VBZ any_DT amino_NN acid_NN except_IN proline_NN )_-RRB- 27_CD ._.
Less_RBR abundant_JJ forms_NNS of_IN protein_NN glycosylation_NN include_VBP O_NNP -_HYPH Fucosylation_NNP ,_, O_NNP -_HYPH GlucNAcylation_NNP ,_, and_CC O_NNP -_HYPH Mannosylation_NNP 16_CD ._.
Protein_NN glycan_NN chains_NNS are_VBP often_RB branched_VBN or_CC elongated_VBN and_CC may_MD present_VB sialic_NN acids_NNS ,_, Lewis_NNP blood_NN group_NN related_JJ antigens_NNS or_CC ABO_NNP (_-LRB- H_NN )_-RRB- blood_NN group_NN determinants_NNS as_IN terminal_JJ structures_NNS 28_CD ._.
Other_JJ modifications_NNS may_MD include_VB phosphorylation_NN ,_, O-acetylation_NN of_IN sialic_NN acids_NNS and_CC O_NN -_HYPH sulfation_NN of_IN galactose_NN and_CC N_NN -_HYPH acetylglucosamine_NN residues_NNS ,_, thereby_RB increasing_VBG the_DT structural_JJ complexity_NN of_IN the_DT glycophenotype_NN 29_CD ._.
In_IN addition_NN ,_, protein_NN glycosylation_NN patterns_NNS do_VBP not_RB follow_VB a_DT predefined_VBN template_NN ,_, as_IN they_PRP are_VBP regulated_VBN by_IN several_JJ factors_NNS at_IN the_DT cell_NN and_CC tissue_NN levels_NNS ,_, promptly_RB responding_VBG to_IN physiological_JJ and_CC pathological_JJ changes_NNS 16_CD ._.
#_NN
Given_VBN its_PRP$ key_JJ functional_JJ and_CC biological_JJ role_NN ,_, alterations_NNS in_IN protein_NN glycosylation_NN underlying_VBG oncogenic_JJ transformations_NNS decisively_RB contribute_VBP to_IN the_DT development_NN of_IN more_RBR malignant_JJ characteristics_NNS ,_, such_JJ as_IN cell_NN -_HYPH cell_NN adhesion_NN impairment_NN ,_, enhanced_VBN migration_NN and_CC @_IN @_IN @_IN @_IN @_IN @_IN @_IN @_IN @_IN @_IN been_VBN also_RB implicated_VBN in_IN the_DT activation_NN of_IN intracellular_JJ oncogenic_JJ pathways_NNS and_CC immune_JJ escape_NN ,_, thereby_RB favoring_VBG cancer_NN -_HYPH tolerogenic_JJ immune_JJ responses_NNS 33,34_CD ._.
Particularly_RB ,_, advanced_JJ stage_NN tumors_NNS often_RB overexpress_VBP or_CC promote_VBP the_DT de_FW novo_NNP biosynthesis_NN of_IN immature_JJ and_CC truncated_VBN O_NN -_HYPH glycans_NNS ,_, such_JJ as_IN the_DT Tn_NNP ,_, sialyl_RB -_HYPH Tn_NNP (_-LRB- STn_NNP )_-RRB- ,_, T_NNP and_CC sialyl_NNP -_HYPH T_NNP (_-LRB- ST_NNP )_-RRB- antigens_NNS ,_, due_IN to_IN a_DT premature_JJ stop_NN of_IN the_DT extension_NN of_IN O_NN -_HYPH glycosylation_NN 35_CD -_SYM 37_CD ._.
Oversialylation_RB and_CC fucosylation_NN of_IN glycan_NN chains_NNS are_VBP also_RB frequently_RB observed_VBN in_IN cancer_NN ,_, including_VBG terminal_JJ antigens_NNS like_IN the_DT sialyl_RB -_HYPH LeA_NNP (_-LRB- SLeA_NNP )_-RRB- and_CC sialyl_RB -_HYPH LeX_NNP (_-LRB- SLeX_NNP )_-RRB- 38_CD -_SYM 40_CD ._.
Contrasting_VBG with_IN the_DT tumor_NN ,_, these_DT structures_NNS are_VBP often_RB absent_JJ or_CC just_RB moderately_RB expressed_VBN in_IN the_DT corresponding_VBG healthy_JJ tissues_NNS ,_, holding_VBG potential_NN for_IN selective_JJ targeted_VBN therapeutics_NNS 38_CD ._.
In_IN addition_NN ,_, many_JJ of_IN the_DT proteins_NNS carrying_VBG cancer_NN -_HYPH associated_VBN glycans_NNS may_MD also_RB be_VB she_PRP 'd_VBD into_IN the_DT bloodstream_NN or_CC other_JJ bodily_JJ fluids_NNS ,_, facilitating_VBG non-invasive_JJ detection_NN methods_NNS ._.
#_NN
Despite_IN the_DT key_JJ role_NN played_VBN by_IN glycosylation_NN ,_, clinically_RB approved_VBN and_CC novel_JJ targeted_VBN therapeutic_JJ approaches_NNS for_IN gastric_JJ and_CC colorectal_JJ tumors_NNS have_VBP mostly_RB resulted_VBN from_IN intense_JJ genomic_JJ ,_, transcriptomic_JJ and_CC proteomic_JJ studies_NNS ._.
Moreover_RB ,_, few_JJ @_IN @_IN @_IN @_IN @_IN @_IN @_IN @_IN @_IN @_IN of_IN gastric_JJ and_CC colorectal_JJ tumors_NNS ,_, mostly_RB due_IN to_IN its_PRP$ intrinsic_JJ molecular_NN complexity_NN ._.
This_DT has_VBZ significantly_RB delayed_VBN the_DT development_NN and_CC translation_NN of_IN glycan_NN -_HYPH based_VBN diagnostic_JJ and_CC therapeutic_JJ solutions_NNS to_IN clinical_JJ routine_NN ._.
Recently_RB ,_, the_DT simplification_NN and_CC standardization_NN of_IN glycobiology_NN -_HYPH based_VBN methods_NNS have_VBP provided_VBN powerful_JJ analytical_JJ tools_NNS to_TO improve_VB our_PRP$ understanding_NN of_IN glycosylation_NN alterations_NNS on_IN specific_JJ cancer_NN -_HYPH associated_VBN proteins_NNS ._.
This_DT review_NN summarizes_VBZ recent_JJ insights_NNS from_IN innovative_JJ research_NN on_IN the_DT glycobiology_NN of_IN gastric_JJ and_CC colorectal_JJ tumors_NNS ._.
It_PRP emphasizes_VBZ the_DT O_NN -_HYPH glycome_NN and_CC glycoproteome_NN ,_, envisaging_VBG the_DT identification_NN of_IN more_RBR specific_JJ cancer_NN glycobiomakers_NNS and_CC the_DT development_NN of_IN innovative_JJ therapeutic_JJ strategies_NNS ._.
Furthermore_RB ,_, it_PRP comprehensively_RB discusses_VBZ the_DT implications_NNS of_IN combining_VBG glycosylation_NN ,_, large_JJ scale_NN genomics_NNS ,_, transcriptomics_NNS and_CC metabolomics_NNS toward_IN true_JJ precision_NN medicine_NN settings_NNS ._.
#_NN Protein_NN glycosylation_NN in_IN gastrointestinal_JJ cancer_NN :_: molecular_NN mechanisms_NNS underlying_VBG the_DT aberrant_JJ glycan_NN biosynthesis_NN #_NN
Perhaps_RB the_DT most_RBS studied_VBN cancer_NN -_HYPH associated_VBN glycoepitopes_NNS in_IN gastric_JJ and_CC colorectal_JJ cancers_NNS derive_VBP from_IN a_DT premature_JJ stop_NN in_IN the_DT elongation_NN of_IN protein_NN O_IN -_HYPH GalNAc_NNP glycosylation_NN 16,37,41_CD ._.
These_DT antigens_NNS have_VBP been_VBN classically_RB termed_VBN as_IN simple_JJ mucin_NN -_HYPH type_NN O_NN -_HYPH glycans_NNS ,_, reflecting_VBG the_DT abundance_NN of_IN this_DT type_NN of_IN glycosylation_NN in_IN mucins_NNS ._.
Nevertheless_RB ,_, these_DT types_NNS of_IN glycans_NNS @_IN @_IN @_IN @_IN @_IN @_IN @_IN @_IN @_IN @_IN protein_NNP expressing_VBG O_IN -_HYPH glycosylation_NN sites_NNS ._.
O_NNP -_HYPH GalNAc_NNP glycan_NN biosynthesis_NN can_MD be_VB initiated_VBN by_IN up_RP to_IN 20_CD polypeptide_NN GalNAc_NNP transferases_NNS (_-LRB- GalNAc_NNP -_HYPH Ts_NNP )_-RRB- ,_, which_WDT are_VBP responsible_JJ for_IN catalyzing_VBG the_DT transfer_NN of_IN a_DT N_FW -_HYPH acetylgalactosamine_JJ residue_NN from_IN UDP_NNP -_HYPH GalNAc_NNP to_IN the_DT hydroxyl_NN group_NN of_IN Ser_NNP or_CC Thr_NNP ,_, originating_VBG the_DT Tn_NNP antigen_NN (_-LRB- Fig._NNP 1_CD )_-RRB- 42_CD -_SYM 44_CD ._.
The_DT different_JJ GalNAcTs_NNPS present_VBP a_DT cell_NN and_CC tissue_NN -_HYPH specific_JJ expression_NN 45_CD ,_, showing_VBG distinct_JJ and_CC partially_RB overlapping_VBG peptide_NN substrate_NN specificities_NNS that_WDT are_VBP crucial_JJ for_IN O_NN -_HYPH glycosites_NNS definition_NN 46_CD ._.
There_EX have_VBP been_VBN reports_NNS of_IN an_DT increased_VBN density_NN of_IN O_NN -_HYPH glycans_NNS in_IN gastric_NN and_CC colon_NN tumors_NNS ,_, resulting_VBG from_IN an_DT increased_VBN GalNAc_NN -_HYPH Ts_NN activity_NN in_IN tumor_NN cells_NNS compared_VBN to_IN normal_JJ cells_NNS 20,47_CD ._.
In_IN most_RBS normal_JJ gastrointestinal_JJ cells_NNS ,_, the_DT Tn_NNP antigen_NN is_VBZ further_RB elongated_VBN by_IN core_NN 1_CD **25;17515;TOOLONG_CD (_-LRB- C1GalT_NNP )_-RRB- ._.
This_DT reaction_NN originates_VBZ the_DT core_NN 1_CD or_CC Thomsen_NNP -_HYPH Friedenreich_NNP (_-LRB- T_NNP )_-RRB- -_HYPH antigen_NN (_-LRB- Gal1_NNP -_HYPH 3GalNAc_NNP -_HYPH Ser_NNP /_SYM Thr_NNP )_-RRB- ,_, in_IN a_DT process_NN dependent_JJ on_IN the_DT functional_JJ chaperone_NN COSMC_NNP (_-LRB- Fig._NNP 1_CD )_-RRB- 48_CD ._.
The_DT initial_JJ GalNAc_NNP may_MD be_VB extended_VBN and_CC originate_VB the_DT core_NN 3_CD ,_, catalyzed_VBN by_IN **36;17542;TOOLONG_CD 6_CD (_-LRB- 3_CD Gn_NNP -_SYM T6_NNP )_-RRB- ._.